drugset / Trial / NCT00657943

Summary

Type 2 Diabetes Mellitus patients (T2DM) have an increased mortality rate due to macrovascular disease. The primary objective of the study is to evaluate the effect of an 18-month treatment with metformin versus placebo in combination with one of three insulin analogue regimens following a treat-to-target principle. The primary outcome measure is change in wall thickness of the carotic arteries(CIMT)measured by ultrasound. A total of 900 patients with T2DM and HbA1c above 7.5% will be included.

Timeline

Start
2008-04
Primary completion
2012-12
Completion
2012-12

Outcome

Missed primary endpoint

paper Change in the mean carotid IMT did not differ significantly between the groups (between-group difference 0.012 mm (95% CI -0.003 to 0.026), p=0.11). PMID 26916684 ↗

paper Carotid IMT change did not differ between groups (biphasic -0.009 mm (95% CI -0.022 to 0.004), aspart+detemir 0.000 mm (95% CI -0.013 to 0.013), detemir -0.012 mm (95% CI -0.025 to 0.000)). PMID 26916685 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2 g —
Subject insulin aspart Protein / enzyme biologic — —
Subject insulin aspart protamin Unknown — —
Subject insulin detemir Protein / enzyme biologic — —